Literature DB >> 16205568

Frequency and associations of a taut thickened posterior hyaloid, partial vitreomacular separation, and subretinal fluid in patients with diabetic macular edema.

Dhanes Thomas1, Catey Bunce, Consuela Moorman, Alistair H Laidlaw.   

Abstract

PURPOSE: To determine prospectively among patients with diabetic macular edema (DME) the frequency of a clinically evident taut thickened posterior hyaloid (TTPH), optical coherence tomography (OCT) signs suggestive of partial vitreomacular separation (PVMS), and OCT evidence of subretinal fluid (SRF) and to investigate for associations between these findings.
METHODS: In a prospective case series, patients with DME despite previous laser treatment were examined for the presence of a TTPH. OCT was performed to investigate for PVMS and SRF.
RESULTS: One hundred forty patients and eyes were included in the study. A TTPH was present in six patients (4%). PVMS was present in 14 (10%) of 140 patients with DME, of whom 5 also had a TTPH. SRF was present in 15 (11%) of 140 patients, of whom 4 had TTPH. OCT showed that 66% of patients with SRF and DME had neither a clinical TTPH nor partial posterior hyaloid separation.
CONCLUSION: A TTPH was found in 4% of subjects with DME. Partial posterior hyaloid separation and SRF may be found in patients who do not have a TTPH. SRF in patients with DME may not be tractional.

Entities:  

Mesh:

Year:  2005        PMID: 16205568     DOI: 10.1097/00006982-200510000-00011

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  9 in total

1.  Is traction the cause or the effect?

Authors:  David Wong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-12       Impact factor: 3.117

2.  Importance of 3-D image reconstruction of spectral-domain OCT on outcome of grid laser photocoagulation for diffuse diabetic macular edema.

Authors:  Avinoam Ophir; Rana Hanna; Michael R Martinez
Journal:  Int J Ophthalmol       Date:  2013-12-18       Impact factor: 1.779

3.  The incidence and risk factors for the development of vitreomacular interface abnormality in diabetic macular edema treated with intravitreal injection of anti-VEGF.

Authors:  C-K Chang; C-K Cheng; C-H Peng
Journal:  Eye (Lond)       Date:  2017-01-20       Impact factor: 3.775

4.  Reduced effect of anti-vascular endothelial growth factor agents on diabetics with vitreomacular interface abnormalities.

Authors:  Dan Yoon; Irene Rusu; Irene Barbazetto
Journal:  Int Ophthalmol       Date:  2013-11-22       Impact factor: 2.031

5.  En face image-based classification of diabetic macular edema using swept source optical coherence tomography.

Authors:  Atsushi Fujiwara; Yuki Kanzaki; Shuhei Kimura; Mio Hosokawa; Yusuke Shiode; Shinichiro Doi; Kosuke Takahashi; Ryo Matoba; Yuki Morizane
Journal:  Sci Rep       Date:  2021-04-07       Impact factor: 4.379

6.  Comparison of anatomical and functional outcomes of vitrectomy with internal limiting membrane peeling in recalcitrant diabetic macular edema with and without traction in Indian patients.

Authors:  S J Vikas; Divya Agarwal; Sankalp Seth; Aman Kumar; Atul Kumar
Journal:  Indian J Ophthalmol       Date:  2021-11       Impact factor: 1.848

7.  Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study.

Authors:  Vincenza Bonfiglio; Robert Rejdak; Katarzyna Nowomiejska; Sandrine Anne Zweifel; Maximilian Robert Justus Wiest; Giovanni Luca Romano; Claudio Bucolo; Lucia Gozzo; Niccolò Castellino; Clara Patane; Corrado Pizzo; Michele Reibaldi; Andrea Russo; Antonio Longo; Matteo Fallico; Iacopo Macchi; Maria Vadalà; Teresio Avitabile; Ciro Costagliola; Kamil Jonak; Mario Damiano Toro
Journal:  Front Pharmacol       Date:  2022-04-06       Impact factor: 5.988

8.  Association of systemic comorbidity in diabetic serous macular detachment and comparison of various combination therapies in its management.

Authors:  Manoj Soman; Sunil Ganekal; Unnikrishnan Nair; Kgr Nair
Journal:  Clin Ophthalmol       Date:  2013-01-14

9.  Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema.

Authors:  Yun Wong; David H W Steel; Maged S Habib; Alex Stubbing-Moore; Dalvir Bajwa; Peter J Avery
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-12-12       Impact factor: 3.117

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.